Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
Abstract
The current therapeutic antibodies and chimeric antigen receptor (CAR) T cells are capable of recognizing surface antigens, but not of intracellular proteins, thus limiting the target coverage for drug development. To mimic the feature of T-cell receptor (TCR) that recognizes the complex of major histocompatibility class I and peptide on the cell surface derived from the processed intracellular antigen, we used NY-ESO-1, a cancer-testis antigen, to develop a TCR-like fully human IgG1 antibody and its derivative, CAR-T cells, for cancer immunotherapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2022
- Source ID
- 10.1136/jitc-2021-004035
Entities
People
- Bingnan Yin
- Changsheng Xing
- Chen Qian
- Helen Y. Wang
- John S. Yu
- Junjun Chu
- Ningyan Zhang
- Rong-Fu Wang
- Tianhao Duan
- Wei Xiong
- Xin Liu
- Yang Du
- Yixiang Xu
- Yuqian Huang
- Zhiqiang An
Organizations
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
- Robert A. Welch Foundation
- United States Department of Defense